(Q37506445)

20 August 2017

1 reference

title

Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide (English)

1 reference

20 August 2017

1 reference

1 reference

Rüdiger Nave

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Clinical Pharmacokinetics

20 August 2017

published in

1 reference

20 August 2017

volume

48

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

243-252

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200948040-00002

20 August 2017

exact match

0 references

cites work

High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200948040-00002

Metabolism of ciclesonide in the upper and lower airways: review of available data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200948040-00002

Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200948040-00002

Ultrafine particle deposition in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200948040-00002

In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices

21 January 2018

1 reference

12 December 2020

Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications

1 reference

12 December 2020

Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide

1 reference

12 December 2020

Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

1 reference

12 December 2020

The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute

1 reference

12 December 2020

Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.

1 reference

12 December 2020

In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates

1 reference

12 December 2020

Comparative in vitro metabolism of 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human.

1 reference

12 December 2020

Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide

1 reference

12 December 2020

Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.

1 reference

12 December 2020

Potential adverse effects of the inhaled corticosteroids

1 reference

12 December 2020

1 reference

12 December 2020

In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide

1 reference

12 December 2020

Systemic side effects of inhaled corticosteroids in patients with asthma

1 reference

12 December 2020

Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis

1 reference

12 December 2020

Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide

1 reference

12 December 2020

Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog

1 reference

12 December 2020

How corticosteroids control inflammation: Quintiles Prize Lecture 2005

1 reference

12 December 2020

Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers.

1 reference

12 December 2020

Treating asthma as an inflammatory disease

1 reference

12 December 2020

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of ciclesonide.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

1 reference

12 December 2020

Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids

1 reference

12 December 2020

Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma

1 reference

12 December 2020

Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)

1 reference

12 December 2020

Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects

1 reference

12 December 2020

Glucocorticoid receptor localization in normal and asthmatic lung

1 reference

12 December 2020

Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma

1 reference

12 December 2020

Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids

1 reference

12 December 2020

Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids

1 reference

12 December 2020

The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide

1 reference

12 December 2020

Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.

1 reference

12 December 2020

Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma

1 reference

12 December 2020

Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety

1 reference

12 December 2020

The global burden of asthma

1 reference

12 December 2020

In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices

1 reference

12 December 2020

Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study

1 reference

12 December 2020

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

1 reference

12 December 2020

National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002

1 reference

12 December 2020

Inhaled corticosteroids: past lessons and future issues

1 reference

12 December 2020

The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue

1 reference

12 December 2020

Molecular mechanisms of corticosteroids in allergic diseases

1 reference

12 December 2020

Ciclesonide: a closer look at its systemic and oropharyngeal safety profile

1 reference

12 December 2020

Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects

1 reference

12 December 2020

Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model

1 reference

12 December 2020

The local side effects of inhaled corticosteroids: current understanding and review of the literature

1 reference

12 December 2020

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma

1 reference

12 December 2020

Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma

1 reference

12 December 2020

Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma

1 reference

12 December 2020

The mechanisms, diagnosis, and management of severe asthma in adults

1 reference

12 December 2020

Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma

1 reference

12 December 2020

Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening

1 reference

12 December 2020

Cytokine mRNA expression in asthma is not restricted to the large airways

1 reference

12 December 2020

Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.

1 reference

12 December 2020

Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients

1 reference

12 December 2020

Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma

1 reference

12 December 2020

10.2165/00003088-200948040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1040017148

0 references

1 reference